Compare Twist Bioscience Corp (TWST) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Visa Inc — how do they compare? Twist Bioscience Corp trades at $163.28 (market cap $10.08B), while Visa Inc trades at $384.2 (market cap $704.20B). The key difference: Visa Inc is far larger — about 69.9× Twist Bioscience Corp's market cap, and Visa Inc pays a 0.71% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Visa Inc for 115 Days on average.
| TWST | V | |
|---|---|---|
Market Cap | $10.08B | $704.20B |
Volume | 4,229,037 | 6,405,857 |
Sector | Health | Financials |
52-Week High | $205.00 | $384.14 |
52-Week Low | $25.45 | $295.52 |
Typical Hold Time | 27 Days | 115 Days |
Enterprise Value | $10.01B | $714.78B |
Dividend Yield | — | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Visa (V) trades at $383.79, up 3.14% today, showing strong momentum near its 52-week high. The stock maintains bullish technical signals with consistent earnings beats and robust fundamentals, including 50.78% net margins and 61.79% ROE. Recent developments include AI-powered commerce initiatives and stablecoin partnerships, positioning Visa at the forefront of payment innovation while maintaining dominant market positioning.
Visa presents a compelling investment case with strong analyst support (85% buy ratings) and a $422.24 price target offering 10% upside. However, elevated valuation multiples (P/E 31.92) and emerging fintech competition require monitoring. The company's consistent execution and AI integration provide growth catalysts, though regulatory scrutiny and payment disruption risks remain considerations for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
